Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;141(5):1892-1895.e6.
doi: 10.1016/j.jaci.2018.01.022. Epub 2018 Feb 7.

Biphasic activation of complement and fibrinolysis during the human nasal allergic response

Ryan S Thwaites  1 , Natasha C Gunawardana  1 , Verena Broich  1 , Elizabeth H Mann  2 , Josefin Ahnström  3 , Gaynor A Campbell  1 , Sarah Lindsley  1 , Nehmat Singh  1 , Tanushree Tunstall  1 , David A Lane  3 , Peter J Openshaw  1 , Catherine M Hawrylowicz  2 , Trevor T Hansel  4
Affiliations

Biphasic activation of complement and fibrinolysis during the human nasal allergic response

Ryan S Thwaites et al. J Allergy Clin Immunol. 2018 May.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
Mast cell degranulation, type II inflammation, complement activation, and fibrinolysis following NAC. Following NAC, nasosorption was used to measure the levels of inflammatory mediators: (A) PGD2 in the first hour and the active complement components C3a, C4a, and C5a over the 8-hour time series. In addition, levels of (B) IL-5, IL-9, and MMP9 are shown over 8 hours. C, D-dimer and u-PA levels post-NAC. Data are represented as medians (n = 15). See Fig E2 for statistical analyses. MMP9, Matrix metalloprotease 9.
Fig 2
Fig 2
Distinct phases of complement activation and fibrinolysis are associated with the EARs and LARs. A, Correlation matrix of the induction of each mediator over the early (0-2 hours) and late (3-8 hours) allergic reactions; blank squares denote insignificant (P > .05) correlations, and color denotes Spearman R value. B, Activation of the complement and coagulation cascades in the EAR and LAR is summarized, along with cells and mediators likely to be implicated in these processes. C, Proposed model of the distinct phases of complement activation in the EARs and LARs. In the early phase, mast cell products trigger complement activation, which, in turn, activates TF, which is abundant in the upper airway, resulting in fibrin deposition. Fibrinolysis rapidly follows, resulting in D-dimer formation. In the late phase, complement may be activated by proteases associated with type II inflammation, similarly triggering fibrin deposition through TF activation. In the late phase, u-PA levels rise, resulting in increased plasmin generation from plasminogen. Plasmin contributes to fibrinolysis and D-dimer formation.
Fig E1
Fig E1
Study design and clinical response. A, Clinical events during NAC. Nasal lavage was performed before allergen administration. Nasosorption sampling and measurements for total nasal symptom score (TNSS) and peak nasal inspiratory flow (PNIF) were taken at 5, 15, 30, 45, and 60 minutes post-NAC, then hourly to 480 minutes. Clinical severity of the allergic reaction was measured by (B) PNIF and (C) TNSS at each time point. N = 15. L, Left; R, right. Data are represented as medians with interquartile ranges.
Fig E2
Fig E2
Mediator levels following NAC. Data from Fig 1 are shown as medians and interquartile ranges. Following NAC, mediators and markers of mast cell degranulation, type II inflammation, complement activation, fibrinolysis, and plasminogen activation were measured: A, PGD2 in the first hour post-NAC. B, IL-5. C, IL-9. The complement components (D) C3a, (E) C4a, and (F) C5a. In addition, levels of (G) D-dimer, (H) MMP9, and (I) urokinase (u-PA) were determined (n = 15). Friedman test with Dunn correction for multiple comparisons, based on the level at each time point relative to those at baseline, was used to determine statistical significance (*P < .05, **P < .01, ***P < .001, ****P < .0001). MMP9, Matrix metalloprotease 9.
Fig E3
Fig E3
Tissue Factor (TF) is persistently present in the human airway at baseline and during allergen exposure. A, TF levels in the nose were indirectly determined using a TF-dependent thrombin generation assay, carried out at baseline and for 8 hours following NAC (n = 4). Data are represented as the median and interquartile range of the subjects, where the thrombin generation of each sample was determined in 3 independent technical replicates. B, To confirm that thrombin generation was TF dependent, thrombin generation was determined in the presence of an inhibitory anti-TF antibody (1 or 10 nM) (n = 8). The thrombin generation of these 8 samples (20 minutes pre- and post-NAC from 4 donors) was determined as the mean of 2 independent technical replicates. Data are shown as mean ± SEM of percentage change from the 0 nM control in each sample. Inhibition data were tested for significance by 1-way ANOVA (****P < .0001).
See this image and copyright information in PMC

References

    1. Cho S.H., Hall I.P., Wheatley A., Dewar J., Abraha D., Del Mundo J. Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma. J Allergy Clin Immunol. 2001;108:212–214. - PubMed
    1. Brims F.J., Chauhan A.J., Higgins B., Shute J.K. Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids. Thorax. 2009;64:1037–1043. - PubMed
    1. Wagers S.S., Norton R.J., Rinaldi L.M., Bates J.H., Sobel B.E., Irvin C.G. Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. J Clin Invest. 2004;114:104–111. - PMC - PubMed
    1. Landi C., Bargagli E., Carleo A., Bianchi L., Gagliardi A., Prasse A. A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls. Proteomics Clin Appl. 2014;8:932–950. - PubMed
    1. Fukuoka Y., Xia H.Z., Sanchez-Munoz L.B., Dellinger A.L., Escribano L., Schwartz L.B. Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5. J Immunol. 2008;180:6307–6316. - PMC - PubMed

Publication types

Substances